United Therapeutics (UTHR) Operating Margin (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Operating Margin data on file, last reported at 41.69% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin fell 650.0% year-over-year to 41.69%; the trailing twelve-month figure through Mar 2026 stood at 45.29% (down 159.0% YoY), and the FY2025 full-year result was 46.89%, down 96.0% from the prior year.
• Operating Margin retreated to 41.69% in Q1 2026, from 45.14% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 62.35% in Q1 2022 to a low of 35.73% in Q4 2022.
• A 5-year average of 48.7% and a median of 48.19% in 2025 frame the typical range for Operating Margin.
• Across the five-year window, Operating Margin surged 7944 bps in 2022 and tumbled 785 bps in 2024, its largest moves.
• Tracing UTHR's Operating Margin over 5 years: stood at 35.73% in 2022, then climbed by 18 bps to 42.31% in 2023, then grew by 15 bps to 48.61% in 2024, then declined by 7 bps to 45.14% in 2025, then retreated by 8 bps to 41.69% in 2026.
• Business Quant data shows UTHR's Operating Margin at 41.69% in Q1 2026, 45.14% in Q4 2025, and 48.59% in Q3 2025.